GMAB Stock Analysis: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$33.02
-0.43 (-1.29%)
▼
5d:
+0.55%
30d:
+14.37%
90d:
+22.89%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GMAB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GMAB shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$51.71
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$32.11
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $33.02, which is considered extended relative to its 30-day fair value range of $28.45 to $32.20. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.8) compared to its historical average (16.7). At these levels, the market is pricing in 7.6% annual earnings growth.
Technical Outlook: Technically, GMAB is in a uptrend. Immediate support is located at $30.52, while resistance sits at $34.19.
Market Sentiment: GMAB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $38.84 (+17.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GMAB is in a uptrend. Immediate support is located at $30.52, while resistance sits at $34.19.
Market Sentiment: GMAB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $38.84 (+17.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$28.45 -
$32.20
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
29.5%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($38.84)
- BULLISH: Expecting earnings turnaround to 7.6% growth with 24.9% revenue growth
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$28.45 -
$32.20
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$30.52
Resistance Level
$34.19
Current Trend
Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.77
Wall Street Target
$38.84
(+17.6%)
Revenue Growth (YoY)
24.9%
Earnings Growth (YoY)
-9.4%
Profit Margin
19.1%
Valuation Premium vs History
+7.6% premium
PE vs Historical
20.8 vs 16.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.6%
(market-implied from PE analysis)
1-Year Target
$35.53
(+8%)
2-Year Target
$38.23
(+16%)
3-Year Target
$41.14
(+25%)
3-Yr Target (if PE normalizes)
(PE: 21→17)
PE COMPRESSION
$33.08
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.8, Growth: 40.7%)
$91.99
(+179%)
Base:
(SPY PE: 20.1, Growth: 40.7%)
$88.81
(+169%)
Bear:
(PE: 16.7, Growth: 40.7%)
$73.97
(+124%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (27x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Trailing PE: 26.94 | Current EPS (TTM): $1.24
Bull Case
$47.12
(+41%)
Analyst growth 28.2%, PE expands to 29.6
Base Case
$42.84
(+28%)
Market implied 28.2%, PE stable at 26.9
Bear Case
$22.72
(-32%)
Severe decline -20.0%, PE contracts to 22.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 24, 2026 5:03 PM ET
Data refreshes hourly during market hours. Next update: 6:03 PM
Data refreshes hourly during market hours. Next update: 6:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 48 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 37 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 40 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 62 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 33 SELL |
